ArticleJournal of clinical neurology (Seoul, Korea)2026
Prospective Study of Botulinum Toxin Effects on Nonmotor Symptoms and Quality of Life in Thai Patients With Craniocervical Dystonia.
Article in Journal of clinical neurology (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
background and purposeCraniocervical dystonia (CCD) comprises focal and segmental dystonia involving the cranial, facial, and cervical muscles. Beyond abnormal movements, affected patients frequently experience nonmotor symptoms (NMS) that profoundly affect their quality of life (QoL). This study aimed to determine the prevalence of NMS and the therapeutic effects of botulinum toxin (BoNT) injections on NMS and QoL in Thai patients with CCD.
methodsThis prospective cohort study included 28 patients with CCD and 29 healthy controls (HC). Demographic data, dystonia severity, NMS, and QoL were assessed before and 1 month after BoNT treatment using the Thammasat University Non-Motor Symptoms Questionnaire (TU-NMSQuest) and the Thai version of the EuroQol-5 Dimension-5 Level (EQ-5D-5L).
resultsThe reported NMS burden was significantly higher in patients with CCD than in HC (10.89±6.05 vs. 8.00±4.15, mean±standard deviation;
conclusionsNMS are common in CCD and contribute markedly to worse QoL. BoNT therapy provides benefits beyond controlling motor symptoms by alleviating NMS and improving overall well-being. Comprehensive management strategies for CCD should integrate the systematic assessment and treatment of NMS in order to optimize patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.